Some other points of interest made by Damien were (sorry if they are already common knowledge): (1) there is still some life in Relenza with expected 50/50 rebalancing of stockpiles expected in next 12 mths or so. (2)BTA798 expected market size of about $600m - not quite a blockbuster without common cold cure approval that Damien says is out of the question approvalwise- will be licenced. (3) BARDA contract includes a 7% margin to Biota - I think an annual revenue source comparable to what we have seen recently from Relenza and Inavir. (4) Damian/BTA views Lani as having 2 distinct markets (a) Stockpile market which will be retained by BTA; and (b) Retail market which BTA intends to licence to big pharma with the necessary sales force to address the dispersed customer base. (5) Lani Milestone $US3m with DS sales topping Y10billion expected to be achieved soon if not from the recent flu season.
BTA Price at posting:
84.0¢ Sentiment: LT Buy Disclosure: Held
